Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer

Yasemin Sanli; Katherine Zukotynski; Erik Mittra; Delphine L. Chen; Helen Nadel; Ryan D. Niederkohr; Rathan M. Subramaniam

doi:10.1097/RLU.0000000000002247

Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer

Yasemin Sanli
, Katherine Zukotynski
, Erik Mittra
, Delphine L. Chen
, Helen Nadel
, Ryan D. Niederkohr
, Rathan M. Subramaniam

Division of Radiological Sciences

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of ¹⁸F-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy ¹⁸F-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus-related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.

Original language	English
Pages (from-to)	E439-E452
Journal	Clinical nuclear medicine
Volume	43
Issue number	12
DOIs	https://doi.org/10.1097/RLU.0000000000002247
State	Published - Dec 1 2018

Keywords

PET/CT
PET/MR
head and neck cancer

Access to Document

10.1097/RLU.0000000000002247

Cite this

@article{2e6e35e440c84a32b038a9c2261d798d,

title = "Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer",

abstract = "There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of 18F-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy 18F-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus-related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.",

keywords = "PET/CT, PET/MR, head and neck cancer",

author = "Yasemin Sanli and Katherine Zukotynski and Erik Mittra and Chen, \{Delphine L.\} and Helen Nadel and Niederkohr, \{Ryan D.\} and Subramaniam, \{Rathan M.\}",

year = "2018",

month = dec,

day = "1",

doi = "10.1097/RLU.0000000000002247",

language = "English",

volume = "43",

pages = "E439--E452",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

number = "12",

}

TY - JOUR

T1 - Update 2018

T2 - 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer

AU - Sanli, Yasemin

AU - Zukotynski, Katherine

AU - Mittra, Erik

AU - Chen, Delphine L.

AU - Nadel, Helen

AU - Niederkohr, Ryan D.

AU - Subramaniam, Rathan M.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of 18F-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy 18F-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus-related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.

AB - There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of 18F-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy 18F-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus-related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.

KW - PET/CT

KW - PET/MR

KW - head and neck cancer

UR - https://www.scopus.com/pages/publications/85056267269

U2 - 10.1097/RLU.0000000000002247

DO - 10.1097/RLU.0000000000002247

M3 - Article

C2 - 30394934

AN - SCOPUS:85056267269

SN - 0363-9762

VL - 43

SP - E439-E452

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 12

ER -

Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this